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ABSTRACT
Introduction and aim: Increasing numbers of students are reportedly using prescription medications
to enhance cognition. This study aimed to generate qualitative data on UK students’ understandings
and perspectives of the risks and benefits surrounding so-called ‘study drugs’ (particularly, modafinil).
Design and methods: Fifteen undergraduate students studying biomedical science subjects were
interviewed about their perspectives on study drugs. Interviews were recorded and transcribed for the-
matic analysis. Users and non-users were included in the sample.
Results: The prescription status and comparisons to other legal and illicit stimulants informed accounts
of the (lack of) risks associated with study drugs, legitimising use. The customisation of sleep(iness)
and wakefulness was described as a key benefit of study drug use. Drivers of use related to university
pressures and desires to increase productivity. In periods of heightened stress, such as examinations,
students reported altered practices and perspectives on risk.
Discussion and conclusions: We noted the contextual nature of students’ use and risk appraisals, with
fluctuating social contexts and pressures over time being capable of altering prior assessments and cur-
rent practices (including the legitimisation of study drug consumption). Further, we highlighted the
degree to which students leveraged their biomedical and experiential expertise to account for drug
consumption.
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Modafinil and Adderall are psychostimulants used to treat
narcolepsy and attention deficit hyperactivity disorder
(ADHD) respectively. Yet, as we know, drugs developed to
treat medical categories can be used to enhance aspects of
social life (Elliott, 2011). While there is evidence that these
drugs elicit cognitive effects in their target populations, far
more doubt exists regarding whether they advance cognition
in ‘healthy’ populations (Ilieva, Hook, & Farah, 2015).
However, the notion that these drugs improve cognition in
unaffected individuals is prevalent in the media (Coveney,
Nerlich, & Martin, 2009; Forlini & Racine, 2009a), and poten-
tially informs the perceptions of university students.
Stimulants have been described as ‘study drugs’, and used
during, for instance, periods of high stress (e.g. exams and
deadlines) (Hildt, Lieb, & Franke, 2014). In such situations,
pharmaceuticals have been employed to improve academic
performance through increased concentration, alertness, and
levels of comprehension (DeSantis, Noar, & Webb, 2010;
Vrecko, 2013).
While the medical use of modafinil has been restricted
even further following a revised risk-benefit profile, suggest-
ing deleterious side-effects, students’ use is allegedly increas-
ing (DeSantis, Webb, & Noar, 2008; European Medicines
Agency, 2010). Some commentators have regarded non-pre-
scription uses of pharmaceuticals as study drugs as danger-
ous and necessitating action (McCabe, Knight, Teter, &
Wechsler, 2005; White, Becker-Blease, & Grace-Bishop, 2006).
Usage has thus become highly debated, though - as Racine,
Rubio, Chandler, Forlini, and Lucke (2014) point out -
analyses of this can be rather speculative. Analysis without
interrogation of students’ own accounts of study drug (non-
)use necessarily comes with assumptions about perceptions
and practices that could be distant from lived experience
(Ketchum, 2013; Morrison, 2015; Pickersgill & Hogle, 2015).
Consequently, it is imperative to localise evaluations of stu-
dent practices within the specific contexts in which they
occur and to consider wider sociocultural environments
(Shook, Galvagni, & Giordano, 2014). Through considering the
specific contexts, values, and understandings that underlie
students’ consumption practices (including a lack of
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consumption) and discourses of legitimation, qualitative stud-
ies can contribute actual and potential user perspectives and
experiences to policy and ethical debates.
This paper draws on data obtained from qualitative inter-
views with UK undergraduates, and seeks to expand current
understanding of how university students perceive and negoti-
ate the risks and benefits of study drugs, particularly modafinil.
It seeks to contribute to debates regarding how students legit-
imise and account for their use (or not) of study drugs, and
how patterns of (contingent) consumption are presented as
relating to their shifting educational contexts.
Background
Our analysis contributes to empirical studies of study drug
use. It also relates to sociological and other social scientific
writings on lay knowledge of biomedical substances and
practices, and recent debates about pharmaceuticalisation;
i.e. ‘the translation or transformation of human conditions,
capabilities, and capacities into opportunities for pharmaceut-
ical intervention’ (Williams, Martin, & Gabe, 2011: 711). Below,
we introduce each of these literatures, in turn, dwelling in
particular on prior work on study drug use.
In the US, Dupont, Coleman, Bucher, and Wilford (2008)
found that 5.3% of US students they surveyed had made use
of the stimulant methylphenidate (e.g. Ritalin) for nonmedical
reasons at least once. This included for recreational reasons.
Further US research from DeSantis et al. (2008) found that of
1811 undergraduates surveyed, 34% reported illicitly consum-
ing prescription stimulants. Different US studies have also
highlighted similar means of accounting for the use of pre-
scription stimulants, e.g. via legitimating discourses that
minimise risk including through comparison with legally-
obtainable substances (Cutler, 2014; DeSantis & Hane, 2010).
National differences in actual practices of ‘study drug’ use,
however, imply the need for case studies across nations. For
instance, Forlini, Schildmann, Roser, Beranek, and Vollmann
(2015) noted that despite widespread knowledge of prescrip-
tion stimulants for the purposes of cognitive enhancement,
only 2.2% of their sample of German university students con-
sumed these. In a survey reported by Singh, Bard, and
Jackson (2014: 1), a ‘substantial majority of students in the
UK and Ireland were unaware of and/or uninterested’ in con-
suming modafinil, methylphenidate or Adderall for purposes
of augmenting cognition.
Though emerging evidence suggests differences in the
incidence of consumption between different cultural con-
texts, there do seem to be some key similarities in terms of
the nature of drug use. Specifically, Forlini and colleagues
found that exams ‘and competitive situations were predomin-
ant motivators of use’ (Forlini et al., 2015: 83; Forlini &
Racine, 2009b). Eickenhorst, Vitzthum, Klapp, Groneberg, and
Mache (2012) and Hildt et al. (2014) obtained similar results
in Germany. In the US, DeSantis et al. (2010) found too that
stimulants were leveraged to manage ‘periods of high aca-
demic stress’, for purposes of both reducing fatigue and
enhancing cognition (see also Kolar, 2015). Qualitative and
survey data obtained by Hupli, Didziokait _e, and Ydema
(2016) indicate similar patterns for university students in
Lithuania and the Netherlands, and likewise Partridge, Bell,
Lucke, and Hall (2013) for Australian students.
Gabe and Bury (1996: 74) have noted that ‘everyday life
comprises knowledgeable people assimilating large amounts
of technical information about risk’. This includes information
about the illicit or off-label use of pharmaceuticals and other
chemical entities for the purposes of pleasure or performance
enhancement. In the case of study drugs, prior research pro-
poses students view prescription stimulants as less harmful
than illicit ‘hard’ drugs (Judson & Langdon, 2009). This per-
ception rests on the prescription status of drugs, symbolising
medicine’s endorsement of their safety (Looby, Kassman, &
Earleywine, 2014). Further, concerns have arisen over the
extent to which users are informed of, and appreciate, the
risks (DeSouza, 2015; Ragan, Bard, Singh, & Independent
Scientific Committee on Drugs, 2013). In sum, there could be
reasons to think that the ‘lay pharmacology’ (Webster,
Douglas, & Lewis, 2009) of study-drug users is significantly
different to the credentialled pharmacological knowledge of
biomedical experts.
Despite these worries, evidence from case studies beyond
the realms of study drugs suggest that different kinds of
expertise about study drugs could be produced and
expressed by users, and put to various ends (e.g. justifying,
moderating, and curtailing use). As Hall, Grogan, and Gough
(2016) have shown for the case of bodybuilders’ use of syn-
thol, pharmaceutical discourses can be engaged with and
leveraged to develop and perform credibility and legitimacy.
Bancroft and Reid (2016) have also illustrated how scientific
knowledge about illegal drugs is developed and deployed on
internet user forums to discuss product quality. Such expert-
ise is not only displayed to others, but can also form part of
how the use actually occurs. In research by R€onk€a and
Katainen (2017), the discourse of internet forum users indi-
cates how scientific and experiential expertise contributes to
developing ‘pharmaceutical competences’ (R€onk€a & Katainen,
2017: 62) and is brought to bear on consumption practices.
Penn (2014) has illuminated how experiential knowledge of
the effects of illegal drugs on bodies can also be leveraged
to intervene in political campaigns that in Canada have
reshaped legal access to cannabis. It is thus important to
attend to if, and how, university students assemble and/or
deploy different kinds of knowledge to account for their con-
sumption of study drugs, not least given the existence of
research which indicates a lack of risk-awareness and formal
pharmacological understanding on the part of users
(DeSouza, 2015; DeSantis et al., 2010).
Finally, Robitaille and Collin (2016) have noted the utility
of pharmaceuticalisation theory for considerations of study
drug use. As indicated above, consumption practices have
been viewed as adaptive responses to the intensified com-
petitiveness of educational environments and wider sociocul-
tural demands (Hogle, 2005; Vargo & Petroczi, 2016).
Coveney (2014) has also shown that drugs are in fact some-
times used to promote sleep, for instance when work
demands make ‘natural’ sleep challenging. Accordingly, both
wakefulness and sleep can be subject to pharmaceutical
intervention, pointing to the complex and dynamic nature of
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pharmaceuticalisation in contemporary societies (Gabe,
Coveney, & Williams, 2016; see also Cloatre & Pickersgill,
2014). This dual role for pharmaceuticals indicates too how,
today, sleep is for many people highly ‘customisable’
(Williams, Coveney, & Gabe, 2013). Our data represent a
timely means of appraising how modafinil is being assimi-
lated into the array of techniques used to customise sleep as
part of a potential pharmaceuticalisation of higher education.
Methodology
This study employed qualitative, semi-structured interviews
to examine students’ understandings and practices surround-
ing the use of non-prescription drugs for study-related pur-
poses. Following ethics approval, audio-recorded interviews
were conducted with 15 students at a UK Russell Group uni-
versity. Undergraduates, rather than postgraduates, were
sampled since they are most frequently depicted as the users
of study drugs (Coveney, Gabe, & Williams, 2011). Students in
their later years of study were purposively recruited, since
they are able to reflect on shifting experiences and workloads
over their time at university. Recruitment was achieved
through an email invitation to all students taking selected
biomedical sciences-related degrees, and only such students
were included in the eventual (convenience) sample.
Interviews were conducted by AS, who was an undergradu-
ate at the time of the study; this enhanced rapport and gen-
erated rich dialogue. The median interview duration was
40minutes (one short interview lasting only 30minutes
nevertheless provided useful data).
Modafinil was selected as the focal pharmaceutical for the
interviews, since unlike Ritalin and Adderall (class B drugs
and illegal to possess) it is not illegal to buy in the UK (HM
Government, 2017). Given this legal position, we assumed
students would be more willing to agree to discuss it than
prohibited drugs. Interviews covered a variety of matters, and
particularly student experiences of their degree to-date (espe-
cially, workload), their familiarity with peers who took study
drugs, their (assumed) motivations for use, the circumstances
in which use occurred, and issues around side-effects and
safety. Patterns of study drug use emerged during the inter-
views; the sample comprised both users (n¼ 10 [3 male, 5
female]) and non-users (n¼ 5 [all female]). All users took
modafinil, with some also having tried Adderall and Ritalin.
By recruiting both users and non-users, we aimed to cast
greater light on what Coveney in her study of non-users’
expectations about modafinil referred to as ‘the cultural
resources, norms, and values that are drawn on to evaluate
the acceptability of new and emerging technologies [of
enhancement]’ (Coveney, 2011). The same topic guide
formed the basis of interviews with both users and
non-users.
Thematic analysis was used to inductively interrogate tran-
scribed data, memos, and a research diary kept by Bryman
(2008). Transcripts and research notes were thoroughly read
numerous times to identify emerging concepts, with analytic
memos made alongside this coding process. Data were
organised into themes, and then arranged under six
meso-level themes: students’ information-seeking practices;
benefits of use; associated risks; study drug use in relation to
illegal drug use; pressures of university life; and, changing
risk assessments in response to contextual shifts. These six
themes were amalgamated into two overarching themes that
encapsulated the data relevant to the research questions: stu-




Overall, students’ understandings of prescription stimulants
accorded with the popular perception that these are a rela-
tively safe means of improving academic performance. In this
section, we analyse how modafinil especially was legitimised
as a ‘safe’ drug with limited side-effects. We consider in par-
ticular the role of contrasts and comparisons in constructing
this pharmaceutical as a (generally) safe substance.
While previous studies have focussed on the widespread
use of pharmaceuticals like Adderall and Ritalin on US cam-
puses (e.g. DeSantis et al., 2010; McCabe et al., 2005), our UK
users all declared modafinil as preferable to these stimulants
(as well as to recreational drugs). Concerns over addiction
and dependency were key components in accounts of these
evaluations and appeared to significantly influence perceived
risk. Students described how the use of Adderall and Ritalin
could result in dependence, and hence these were
approached more cautiously. Modafinil was presented as
non-addictive, and as producing a ‘less systemic effect’ on
the body, with ‘no buzz’. As R1 (user) described: ‘Modafinil is
not addictive, that’s why it’s a lot more preferable to other
study drugs’.
The side-effects that students did discuss (which were
often second-hand accounts) included flushes, headaches,
increased thirst, reduced appetite, and interrupted sleep pat-
terns. Overall, these were not considered significant enough
to be major deterrents. Other students also presented moda-
finil as having limited or no side-effects (and both user and
non-user perceptions were similar in this regard). R2 (user)
reflected: ‘I would say the benefits outweigh the risks; I’ve
not had any negative side effects’. R11 (user) described the
phenomenology of use as follows: ‘you don’t feel high, you
don’t feel like speedy [… ] that’s why I took it, because it
was quite nice and I didn’t feel like I was on drugs’. For this
student, modafinil ‘just feels like you took a cup of coffee
that lasted the whole day’. This made it more effective for
studying, safer, and more pleasant to use. Several students
highlighted that side-effects exist for every substance, and
those of modafinil may be no worse than commonly used
and accepted medications. As one respondent put it, ‘there
are side-effects to everything’ (R13, non-user).
Responding to the question ‘how does modafinil compare
to other stimulants?’, the risk was often articulated in relation
to other study drugs, illicit substances, coffee, and caffeine
pills. Coffee was commonly presented as the exemplar of a
safe and acceptable means of staying awake. Some students
subsequently compared modafinil use to coffee consumption,
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minimising its significance. Several users, in fact, asserted
that the side effects of caffeine were considerably less desir-
able and less conducive to their goal of maintaining an effi-
cient and lengthy period of study. R1 (user), for instance,
noted that modafinil ‘doesn’t make you jitter and shake, not
like if you drink too much coffee’. R2 (user) made a more
forceful distinction between these substances, arguing that
caffeine ‘is definitely more dangerous than modafinil, 100%;
you’ve got billions of people addicted to caffeine. It’s so bad
for you’. However, some non-users diverged from this com-
paratively positive and legitimising account of modafinil vs.
caffeine. R7 (non-user), for instance, rationalised that the
heightened social acceptability and daily use of caffeine were
indicators of safety: ‘I drink coffee, and caffeine’s a drug [… ]
but it’s more socially acceptable; it’s legal and it’s every-
where. And it’s not like taking pills; when I’m drinking coffee,
it’s like a food – a natural thing’.
The fact that modafinil was taken as a pill was described
by one student (R2, user) as implying it should or would be
more potent than, for instance, coffee: ‘the whole process of
swallowing a pill has more significance, you’re like, okay I’ve
taken a pill, therefore, I should be feeling something as it
exerts some sort of effect’. The materiality of modafinil thus
appeared to hold consequences for perceptions of efficacy,
as well as risk: ‘generally, because it’s in pill form, I feel like
you might be more careful with it’ (R8, user). While illicit
drugs can also come in the form of a pill, for some students
this reinforced the status of modafinil as a safe substance. R8
(user), for instance, reflected that ‘I feel like because it comes
packaged properly, it should do less damage, versus recre-
ational drugs where you just get who-knows-what from who-
knows-who’.
Students largely implied that the prescription status of
modafinil increased its safety; after all, it was ‘a medical drug,
not a street drug’ (R2, user). Prescription status could also
provide a reliable and safe means of determining dosage (for
non-medical purpose) and seemed to reinforce perceptions
of safety. R1 (user) described this as follows: ‘if you take less
than what they recommend on the guidelines for the drug,
you assume that you’re not going to experience anything
that’s really bad’. These findings underscore the arguments
found in Coveney et al. (2011) and Cutler (2014), where trust
and authority are invested in medicine and medical institu-
tions to demarcate safe from unsafe pharmaceuticals and
drug practices.
In sum, modafinil use was legitimised through construc-
tions of its side-effects as minor, which related to a general
presentation of the drug as (comparatively) safe. Similar dis-
courses of minimisation and comparison have been found in
some US research (e.g. Cutler, 2014; DeSantis & Hane, 2010).
Constructions of safety were substantiated through respond-
ents’ personal experiences (what Webster et al. (2009) might
refer to as ‘lay pharmacology’), through comparisons and
contrasts (e.g. with other study drugs and caffeine), and
through the status of modafinil as a prescription pill. In the
latter case, the fact that it came as a tablet also underscored
its potential potency. Consequently, the particular materiality
of modafinil connects it with the multiple cultural meanings
to which pharmaceutical objects can be attached
(Martin, 2006).
Leveraging knowledge
In this section, we want to foreground the different kinds of
knowledge that our participants engaged with and leveraged
when substantiating their perspective of modafinil and legiti-
mising practices of consumption. To begin with, we continue
our discussion of how our participants situated this drug
within UK biomedicine, in order to elucidate how under-
standings of pharmaceutical innovation and regulation
played key roles in constructing the ontology of modafinil.
Modafinil’s prescription status denoted a substantial
reduction in risk and more favourable attitudes in compari-
son to illicit drugs (see also Judson & Langdon, 2009; Looby
et al., 2014). Students defended their stance through detail-
ing the stringent testing procedures of clinical phase trials
that must be met in order for drugs to be approved. Thus,
they brought to bear their knowledge about the rigour of
pharmaceutical testing and clinical trials in their adjudications
of the safety and efficacy of study drugs. In doing this,
though, some respondents also destabilised a more generally
expressed perception of modafinil as safe for all users.
Several students distinguished that testing and approval
occurred for use within a specific population and conse-
quently reflected that drugs might elicit different effects in
healthy populations. As R3 (user) put it: ‘studies say that they
don’t do to your brain what they do to the person they’re
designed for, because [… ] they’re designed to fix something
you’re not deficient in’. Relatedly, some students who initially
described perceiving modafinil as safe shifted their percep-
tion of the drug when discussing its prescription status.
Specifically, they described how untested/unapproved appli-
cations of drugs could confer additional risks, and that the
consequences of these might outweigh any benefits. For R13
(non-user), ‘if you need a prescription for something, the
‘powers that be’ have deemed it more dangerous than just
over the counter’.
Contrary to the US students of DeSouza’s (2015) and
DeSantis et al. (2010) research, our UK undergraduate
respondents articulated various degrees of understanding of
the biochemical composition and effects of study drugs.
These could be leveraged to legitimise consumption practi-
ces. Users, in particular, appeared confident in their research
and overall knowledge of the pharmaceuticals they used.
Hupli et al. (2016) have proposed that study drug use is not
the reckless practice some critics condemn it as; similarly, the
students we interviewed asserted that they would not con-
sume drugs without what they considered adequate
research. R9 (user) described this as follows:
building up to taking them [… ] I did quite a lot of research,
weighing up the pros and cons and the differences between all
types of study drugs that were available to me, to decide which
one would suit me best for my personal needs and wants. It
wasn’t a spontaneous decision at all.
Students reported different depths of and sources for
research, but all concurred that information was abundant
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and easily accessible. While some turned to Wikipedia, others
examined primary peer-reviewed papers to conduct their
own analyses of risk-benefit ratios in order to develop what
R€onk€a and Katainen (2017) call ‘pharmaceutical competences’
that were different in kind to ‘lay pharmacology’ (Webster
et al., 2009) constituted through bodily experiences. Several
respondents described the scientific nature of their degree as
having a role in shaping their research into study drugs:
‘coming from a medical sciences background [… ] it would
be warped of me to not know what I was taking before I
started taking it’ (R9, user).
Students that had researched and/or experienced modafinil
emphasised how few, if any, side-effects exist, and presented
them as minimal. Both this research and wider knowledge of
pharmacology were deployed as part of the legitimating reper-
toires of safety discussed in the previous section, such as by
R9 (user): ‘when I was doing research [… ] I couldn’t see any
immediate negative effects from modafinil. The only real con-
cerns were potential sleep deprivation if it’s taken for a long
period of time’. Another user, R5, drew on a biomedical idiom
(i.e. talk of ‘mechanisms’) to authenticate the constructions of
safety via an analogy with coffee (thus employing a similar
comparative trope to the respondents discussed above). As
they put it: ‘people taking [study drugs] and people chugging
coffee, it’s basically the same mechanism [… ] biologically I’d
put them in the same category’.
We can see, then, that several students leveraged and/or
claimed different kinds of knowledge about biomedical
innovation, pharmaceutical regulation, and neurochemical
processes to account for their different perspectives on study
drugs. This knowledge did not necessarily pre-exist consider-
ation of drug consumption; rather, dedicated and specific
research into the psychoactive properties of study drugs
could also shape decision-making about use. In the final sec-
tion, we turn to a closer examination of how and why moda-
finil might be consumed by UK undergraduates, paying
particular attention to the circumstances under which initial
appraisals of the risks and benefits of drug-taking could shift
and change in order to (de)legitimise study drug use.
Enhancing productivity
During the interviews, university life was framed as an envir-
onment of heightened competitiveness, resulting in the feel-
ings of stress and anxiety that were described as rife among
the sample population (particularly regarding future pros-
pects). Students articulated a range of sources of stress,
including self-expectations, familial expectations, time con-
straints, examination timetables, and financial and/or career
considerations. In the words of one respondent: ‘you are up
against all these people [… ] the competition never stops
between who gets the best grade, because who gets the
best grade gets the better job’ (R13, non-user).
Such pressures were accounted for as legitimising and shap-
ing (potential) study drug use: ‘I don’t think [modafinil] was
about in our parents’ generations, but these days everyone is
wanting an extra level. I think that’s just our era; the expecta-
tions of people have gone up’ (R6, user). Students explained
that the convergence of different pressures was significant
enough to warrant, and maybe event necessitate study drug
use. Clashing examinations was one example given:
some people have really shitty exam schedules [… ] and if you
don’t have study drugs for that, you will not pass your exams, it’s
very, very simple [… ] the university puts you in a position where
you feel like you’ve got to do it [… ] when exam days are like
three days apart from each other [… ] you can’t afford to lose a
day because of tiredness [… ] [study drugs] make sure you don’t
crash (R11, user)
Many students linked academic achievement to their self-
worth. However, one non-user explained that they did not
define their value as a student based on their grades, and
consequently felt no compulsion to take study drugs:
if people are placing more emphasis on their grades, then they’re
going to want to do it more [… ] if I don’t do well, it doesn’t
define who I am as a person [… ] but, some people are more
willing to do everything like [take study drugs] [… ] it’s like how
far will people go for grades, I feel it’s a bit of a slippery slope
(R7, non-user)
All interviewees reported improving academic study as the
primary purposes of drug use, particularly valuing improved
focus, increased efficiency, and reduced procrastination. These
effects were judged highly desirable in the context of time
constraints and fatigue approaching exams and deadlines. As
one student reflected, a need exists to be ‘more efficient with
your time if you are under a lot of pressure, to stay awake for
a longer period of time’ (R10, user). This student took modafi-
nil to revise for exams, describing its benefits as follows: ‘I’d
have to do ten hours a day and I just can’t sit for that long,
and then I took [modafinil] and I did [… ] it was amazing’.
A demand for efficiency and increased productivity was
repeatedly presented as an impetus for and means of legiti-
mising study drug use. Users judged their levels of productiv-
ity insufficient and recounted the ability to study for
significantly longer periods with the use of drugs. Additionally,
modafinil use was described by one student as forming part
of a ‘prevention strategy’ to avoid undesirable states of burn-
out or exhaustion (which impair students’ ability to work).
Specifically, modafinil ‘makes you concentrate more [… ] you
just keep on going because you’re in the zone; it just makes
you, the best you on that given day [… ] giving you more
hours in the day to do the stuff you need to do’ (R9, user).
The ability of modafinil to affect wakefulness was well-
known, and carefully used to align with students’ desires to
customise sleep and sleepiness (Williams et al., 2013) in par-
ticular ways. While non-users generally interpreted reduced
appetites and inability to sleep as (albeit minimal) negative
effects, users often accounted for these as benefits: ‘taking
[modafinil] after a certain period of time, you won’t be able
to sleep [… ] it’s one of your uses; you want to increase
focus and [… ] it’s something to stop you falling asleep’ (R1,
user). As they further described:
It’s like downing a Redbull [an energy drink] at 3 am, you know
you’re not going to sleep [… ] you feel like crap the next day
[… ] but your assignment will be done. That’s a student’s life; the
student makes that cost-benefit decision and if the benefits
outweigh the costs, then they’re going to do it (R1, user)
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The prudent planning of consumption was presented as a
means of avoiding unwanted consequences; for instance, the
drug might be consumed later in the day when users strove
for an ‘all-nighter’ (i.e. a period of study lasting throughout
the night). After all, ‘to do an all-nighter, you’re not going to
want to sleep and you also won’t need to eat as well, so
that’s good’ (R9, user).
Importantly, these assessments were flexible: they
changed with shifting circumstances. Students detailed a
kind of threshold of pressure that they felt capable of dealing
with; however, exceeding this limit instigated the search for
an aid to meet the challenges they faced. An initial risk per-
ception regarding study drugs could thus be overridden by a
more pressing need, as illustrated in the extracts below:
I was super against taking them at first…by 2nd year, I was like,
that’s fucking stupid, I need to pass my classes (R1, user)
if you’re in that desperate situation where you just need to get it
done, then of course you’re going to take something that means
you’ll be able to get it done in that time. Because nobody wants
to submit something late [… ] a 5% [reduction in numeric grade]
penalty will affect your overall university grade (R9, user)
Students also underscored the influence of drug availability
in decision-making. If students found themselves in a situation
where drugs were readily obtainable, the potential immediacy
of stress resolution could lead students to re-assess their ini-
tial stance:
If my friend was sitting in the library opposite me and I had a
deadline in two days and was freaking out [… ] and they said,
look, I’ve got some modafinil, it’ll help you concentrate [… ] I’d
still have that reservation, like, that’s bad, I shouldn’t do that, but
also I’d, be, like, that would really help [… ] it’s never been
accessible to the point where it’s like, okay, I’ll just take it, but if I
was in that situation, I would definitely be tempted (R4, non-user)
To summarise, study drug users primarily accounted for
consumption in terms of work-related goals. Students
described study drugs as an effective means of controlling
and managing pressures and external stressors encountered in
university education (Forlini et al., 2015; Robitaille & Collin,
2016), through customising sleep and sleepiness (Williams
et al., 2013). Specifically, users strongly endorsed modafinil’s
ability to increase focus, thereby extending the feasible dur-
ation of study. The use of study drugs was legitimated as a
means of coping with the demands and rigours of university
life. Such pressures have also been highlighted in other
Australian, European, and US studies (e.g. Eickenhorst et al.,
2012; Hildt et al., 2014; Hupli et al., 2016; Jensen, Forlini,
Partridge, & Hall, 2016; Kolar, 2015; Partridge et al., 2013).
Students’ risk-benefit assessments about study drugs were
accounted for as contingent on the magnitude of the afore-
mentioned pressures, and consequently were not fixed. This
was apparent in users’ accounts, and in some non-users’ con-
templations of scenarios where they would feel impelled to
pursue pharmacological coping strategies.
Conclusion
This article has explored university students’ perspectives
around the risks and benefits that accompany ‘study drug’ use,
and the knowledge and experiences bought to bear on devel-
oping and accounting for these. An important aspect of
our research has been the inclusion of both users and
non-users: we have demonstrated a resonance between their
accounts of why students might consume study drugs, and
what the potential harms and advantages are conceived
as being.
Users tended to develop pharmaceutical competences
(R€onk€a & Katainen, 2017), and leveraged pharmacological
knowledge to explain that Ritalin and Adderall demonstrate
varying levels of addictiveness, but that there is no reported
dependence for modafinil. As a consequence of this and the
limited side-effects of modafinil (some of which were pre-
sented as positives), student users stated that they tended to
imbibe that rather than other study drugs. DeSouza (2015)
has suggested that undergraduates do not show particular
concern for potential risks to study drugs; however, one
interpretation of our data is that users negotiate the harms
of different study drugs and choose the one that poses the
least risk. Another interpretation is that accounts of the risks
of other drugs are used as a post hoc justification for the
consumption of modafinil, which is a more accessible
pharmaceutical in a UK context, as part of a broader strategy
of legitimation for study drug use per se. Future research
should aim to cast greater light on these divergent, but not
necessarily mutually exclusive, interpretations.
Underscoring how different meanings can adhere to the
same pharmaceutical object (Martin, 2006), the fact that
study drugs were present in the form of a pill was received
in various ways by different participants in our study, becom-
ing imbricated within different formulations of, and for
assessing risk. For example, the fact modafinil came in a pill
form could be read as signalling its (worrying) potency, it
could also be interpreted as communicating safety.
Discourses of minimisation and comparison have been found
in some US research (e.g. Cutler, 2014; DeSantis & Hane,
2010) when users account for their consumption practices;
similar patterns were evident in our study, with coffee fre-
quently deployed as a comparison point to signal the safety
and efficacy of modafinil (and hence to legitimate its use).
Associated with rhetorical minimisation, users leveraged
experiential, bodily knowledge about the effects of study
drugs (‘lay pharmacology’; Webster et al., 2009) to account
for their general use of study drugs and their specific pat-
terns of consumption, as well as, more formalised pharmaco-
logical and wider knowledge. Other research has indicated a
lack of risk-awareness and formal pharmacological under-
standing on the part of users (DeSouza, 2015; DeSantis et al.,
2010). Our attention to an elucidation of the leveraging of
different forms of knowledge by study drug users suggests
alternate ways of exploring understandings and perspectives
on risk and modes of legitimisation by study drug users.
Students reported intensified stress and anxiety levels
around exam times, and accounted for these as altering how
risks and benefits were weighed, shifting student’s assess-
ments over time. The students we interviewed similarly pre-
sented the standards they had to meet to secure particular
futures for themselves as set higher than for previous genera-
tions, and implied that an inability to meet these as a
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personal deficit that needed to be overcome, including via
the use of drugs. Our respondents also spoke of being more
willing to compromise on initial risk-assessments in order to
complete pressing workloads. This finding aligns with
research emphasising the pursuit of productivity underlying
study drug use and claims that the progressive pharmaceu-
ticalisation of society (Williams et al., 2011) is now extending
into higher education (Petersen, Norgaard, & Traulsen, 2015;
Vargo & Petroczi, 2016). Individuals increasingly conceive the
ability to stay awake and focus as being amenable to
pharmacological manipulation (Coveney et al., 2009), with
sleep being customisable (Williams et al., 2013) in order to
meet desired goals. Hogle (2005: 697) has described
demands ‘for a new type of body’ that ‘needs little sleep and
can work harder’ (see also Collin, 2016). While our data does
not enable us to make clear statements about whether (or
not) theories about the pharmaceuticalisation of higher edu-
cation are supported, it is certainly the case that (a) study
drugs are now part of the (longstanding) array of strategies
used by at least some students to customise sleep(iness) and
wakefulness, and (b) the pressures of university life are a
readily available resource for constructing narratives of legit-
imation for drug use. Further, it was the facility of study
drugs to modulate sleep and sleepiness that tended to be
emphasised over any generalised ‘cognitive enhancement’
(i.e. drugs seem largely positioned to help students work
harder, but necessary to be ‘smarter’).
To summarise, the findings of this study have augmented
the existing literature examining student perspectives on ‘study
drugs’, reinforcing existing claims about the extent to which
drug practices are linked with situational pressures (DeSantis
et al., 2010; Eickenhorst et al., 2012; Forlini & Racine, 2009b,
Forlini et al., 2015; Hildt et al., 2014; Hupli et al., 2016; Partridge
et al., 2013), and underscoring how consumption is largely
aimed at customising sleep and sleepiness (Williams et al.,
2013) and not necessarily the enhancement of cognition per se.
We have additionally drawn attention to how lay pharmacology
(Webster et al., 2009) and pharmaceutical competences (R€onk€a
& Katainen, 2017) are developed and deployed to legitimate
and account for - and likely shape - drug use.
Implications
Given our findings, we consider that there is at least the
potential for UK educators and institutions of higher educa-
tion to consider policy in relation to study-related pharma-
ceutical practices. However, we are also mindful of Forlini
et al. (2015) scholarship, which presents a ‘challenge [to] the
assumption that policy on neuroenhancement is necessary
for academic environments’ (Forlini et al., 2015: 83). If any
endeavours are advanced by institutions (e.g. in terms of
harm reduction or health education policies) - and we are
not necessarily advocating that they should be - we feel
strongly that education leaders need to refrain from an exclu-
sive emphasis on the individual and personal practices of
undergraduates. Instead, they need to focus on the temporal-
ities of university life that generate moments of heightened
anxiety and stress of the kind that our respondents account
for as enjoining study drug use. Infrastructural innovations in
this regard might include the restructuring of assessment
timetables in order to flatten out some of the peaks and
troughs of examinations and deadlines throughout the aca-
demic year. In essence, any initiative geared towards inter-
vening in study-drug use should not be divorced from wider
endeavours to enhance student mental health and wellbeing
(see relatedly Jensen et al., 2016). Moreover, universities must
refrain from individualising student healthcare such that they
undergraduates are regarded as the exclusive guardians of
their own wellbeing within structures of high education that
can act as impediments to health and welfare.
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